Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy
作者机构：Division of Medical OncologyDepartment of Internal MedicineSeoul St.Mary's HospitalCollege of MedicineThe Catholic University of KoreaSeoul 06591South Korea Catholic Cancer Research InstituteCollege of MedicineThe Catholic University of KoreaSeoul 06591South Korea
出 版 物：《World Journal of Gastrointestinal Oncology》 (世界胃肠肿瘤学杂志（英文版）（电子版）)
年 卷 期：2021年第13卷第8期
页 面：915-928页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Pancreatic adenocarcinoma Serum carbohydrate antigen 19-9 Neutrophil-tolymphocyte ratio Multivariate analysis Prognosis Chemotherapy
摘 要：BACKGROUND A decline in serum carbohydrate antigen 19-9(CA19-9)levels during systemic chemotherapy is considered as a prognostic marker for patients with advanced pancreatic ***-to-lymphocyte ratio(NLR)has been extensively studied as a simple and useful indicator of prognosis in various cancers including pancreatic *** To assess the prognostic significance of NLR and CA19-9 in patients with advanced pancreatic adenocarcinoma received first-line chemotherapy according to CA19-9 *** We retrospectively analyzed patients diagnosed with advanced pancreatic cancer who received first-line chemotherapy between January 2010 and July 2017 at the Catholic University of Seoul ***’s *** were divided according to CA19-9 positivity(CA19-9-positive vs-negative groups)and pre-and posttreatment NLR *** determine cut-off value of NLR and CA19-9 reduction,time-dependent receiver operating characteristic curve was *** evaluated overall survival(OS)and progression-free survival(PFS)for each group using Kaplan-Meier method,and we performed multivariate analyses on the entire *** We included 271 patients in this ***-off value of NLR and CA19-9 reduction was determined as 2.62 and 18%.Multivariate analysis showed that post-treatment NLR2.62 and reduction of≥18%of baseline CA19-9 were significantly associated with OS and ***-treatment NLR≥2.62 showed hazard ratio(HR)of 2.47[95%confidence interval(CI):1.84-3.32,P0.001]and CA19-9 decline(≥18%)showed HR of 0.51(95%CI:0.39-0.67,P0.001)for *** CA19-9-positive patients were divided into groups according to CA19-9 response(responder vs non-responder)and post-treatment NLR(2.62 vs≥2.62),CA19-9 responder and post-treatment NLR2.62 group showed better survival than CA19-9 non-responder and post-treatment NLR≥2.62 group(OS 11.0 mo vs 3.9 mo,P0.001;PFS 6.3 mo vs 2.0 mo,P0.001).The combination of CA19-9 decline and post-treatment NLR showed a significant c
维普期刊数据库